Advances in Development of Drug Treatment for Hemophilia with Inhibitors
6
Issued Date
2024-01-01
Resource Type
eISSN
25759108
Scopus ID
2-s2.0-85208668474
Journal Title
ACS Pharmacology and Translational Science
Rights Holder(s)
SCOPUS
Bibliographic Citation
ACS Pharmacology and Translational Science (2024)
Suggested Citation
Wichaiyo S. Advances in Development of Drug Treatment for Hemophilia with Inhibitors. ACS Pharmacology and Translational Science (2024). doi:10.1021/acsptsci.4c00560 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102068
Title
Advances in Development of Drug Treatment for Hemophilia with Inhibitors
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Patients with hemophilia A and B who have inhibitors face limited treatment options, because replacement therapy with clotting factor VIII or IX concentrates is ineffective, particularly for patients with high-titer inhibitors. Current mainstay therapies include immune tolerance induction (through frequent injections of clotting factor VIII or IX concentrates) to eradicate inhibitors and bypassing agents (such as recombinant activated clotting factor VII and activated prothrombin complex concentrates) for the prevention and treatment of bleeding episodes. The use of these agents typically requires intravenous injections and sometimes hospitalization, which can be burdensome for patients. More recently, emicizumab, a bispecific antibody that mimics the function of activated clotting factor VIII, has demonstrated favorable efficacy for prophylaxis in patients with hemophilia A and inhibitors, representing a promising new therapeutic strategy. Ongoing research aims to discover and develop easy-to-use nonfactor agents for managing hemophilia with inhibitors. This review summarizes the current understanding of the pathophysiology of inhibitor development in hemophilia, outlines existing treatment options, and discusses advancements in novel therapeutic biologics, including a recombinant activated clotting factor VII variant (marzeptacog alfa), a new bispecific antibody (Mim8), antitissue factor pathway inhibitor antibodies (concizumab and marstacimab), and small interfering RNA targeting antithrombin (fitusiran). All of these agents are administered subcutaneously, with some offering the convenience of less frequent dosing (e.g., weekly or monthly). These potential drug candidates may provide significant benefits for the prophylaxis or treatment of bleeding disorders in patients with hemophilia and inhibitors.